Journal article

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial

Chantal Mathieu, Bernard Zinman, Joanna Udden Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode

Diabetes Care | AMER DIABETES ASSOC | Published : 2016


OBJECTIVE: To investigate whether liraglutide added to treat-to-target insulin improves glycemic control and reduces insulin requirements and body weight in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin. RESULTS: HbA1c level was reduced 0.34-0.54% (3.7-5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide -0.20% [95% CI -0.32; -0.07]; 1.2 mg liragl..

View full abstract


Funding Acknowledgements

The authors thank all subjects and ADJUNCT ONE investigators involved in the study. The authors also thank Salvatore Calanna and Thomas Jon Jensen of Novo Nordisk A/S for their review and input to the manuscript and Daniel Hayward of Novo Nordisk A/S for providing medical writing assistance during the preparation of this manuscript. Submission support was provided by Watermeadow Medical, an Ashfield Company, part of UDG Healthcare plc, funded by Novo Nordisk.